Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as OCS-02
licaminlimab · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| licaminlimab | EXPERIMENTAL | 60 mg/mL licaminlimab ophthalmic solution |
| Vehicle | PLACEBO_COMPARATOR | Vehicle of licaminlimab ophthalmic solution |
| Name | Type | Description |
|---|---|---|
| licaminlimab | DRUG | ophthalmic solution 60 mg/mL Subjects will be randomized to receive licaminlimab eye drops three times daily (TID) for 6 weeks. |
| vehicle of OCS-02 | OTHER | inert ophthalmic solution vehicle of OCS-02 Subjects will be randomized to receive vehicle eye drops three times daily (TID) for 6 weeks. |
| Artificial tears | OTHER | Subjects who quality after an initial screening were entered into a run-in phase where they received artificial tears to use three times daily (TID) for approximately 14 days. |
| Artificial Tear Run-in | OTHER | Artificial tear eye drop run-in three times daily (TID) for approximately 14 days. |
| Vehicle of licaminlimab | OTHER | Inert ophthalmic solution vehicle of licaminlimab, three times daily (TID) for 29 days. |
Key Inclusion Criteria: * Physician diagnosis of Dry Eye Disease in the past 6 months * Use of over-the-counter tears * Must agree to genotype testing Key Exclusion Criteria: \- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere ...
Top 4 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | VSJ-110 |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | ABBV-319 |
| Oculis Holding AG | OCS | 1 | PHASE2 | licaminlimab |
| Bausch Health Companies Inc. | BHC | 1 | PHASE2 | BL1107 |
Licaminlimab is being developed for the treatment of dry eye disease, an ophthalmology condition. It is an investigational monoclonal antibody administered as an ophthalmic solution. The drug is currently in Phase 2 clinical development, with two trials conducted in patients with dry eye disease.
Licaminlimab targets tumor necrosis factor alpha, or TNFα. It is a monoclonal antibody designed to bind TNFα, a pro-inflammatory cytokine. By targeting TNFα, licaminlimab aims to reduce inflammation associated with dry eye disease. This mechanism is being evaluated in Phase 2 trials.
Licaminlimab is being developed by Oculis Holding AG, which trades under the ticker OCS. Oculis is a biopharmaceutical company focused on ophthalmology. The company is advancing licaminlimab as an investigational therapy for dry eye disease.
Licaminlimab is in Phase 2 clinical development. It has not been approved by the FDA and remains investigational. Two Phase 2 trials have been conducted: one completed and one currently recruiting. The drug is being evaluated for dry eye disease.
Licaminlimab has been studied in two Phase 2 clinical trials. The completed trial, NCT05896670, evaluated the safety and efficacy of licaminlimab ophthalmic solution in dry eye disease with 122 participants. The ongoing trial, NCT07548632, is recruiting 160 participants in the United States to further evaluate licaminlimab for dry eye disease.